Patient Education

Understand
the category before considering a product or procedure

Regenerative medicine is a broad term covering many different
products, procedures, and areas of research. A structural tissue
allograft is not automatically a stem-cell therapy. An exosome product
is not the same as a stem cell. A peptide may be an FDA-approved
medicine, an investigational compound, or part of a compounded
formulation. A red-light wellness device is different from a medical
device authorized for a specific indication.

The most important first step is to identify exactly what is being
offered.

Structural tissue allografts

An allograft is human tissue recovered from a donor and processed for
use in another person. Depending on the product, source, processing, and
labeling, it may be intended to provide structural support, cover or
protect tissue, or supplement or replace inadequate connective
tissue.

Ask for the exact product name, manufacturer, tissue source,
processing information, labeling, intended use, storage requirements,
and available safety documentation. Do not assume that every
umbilical-cord or placental product contains living stem cells.

Stem-cell therapies

Stem cells can self-renew and develop into specialized cell types.
Hematopoietic stem-cell transplantation is an established therapy for
certain blood, immune-system, and cancer-related conditions. Many other
advertised uses of stem cells remain investigational or unapproved.

Ask whether the proposed product is FDA-approved for the specific
use, part of an FDA-authorized clinical trial, or being offered under
another regulatory framework. FDA warns consumers about unapproved
regenerative products marketed for broad disease-treatment claims.

Exosomes and extracellular
vesicles

Extracellular vesicles are studied as part of cell-to-cell signaling.
Laboratory or preclinical research about a biological mechanism does not
prove that a commercial exosome product is safe or effective for a
specific patient use. FDA states that there are currently no
FDA-approved exosome products.

Peptides and compounded
products

Peptides are short chains of amino acids. Some peptide drugs are
FDA-approved for specific indications; others are investigational or may
be discussed in compounding contexts. Compounded drugs are not
FDA-approved and are not reviewed by FDA for safety, effectiveness, or
quality before marketing.

Patients should ask for the exact active ingredient, whether an
FDA-approved option exists, why a compounded product is being
considered, which licensed pharmacy or outsourcing facility is involved,
what monitoring is required, and what risks or uncertainties apply.

Red and near-infrared light

Photobiomodulation research examines how selected red and
near-infrared wavelengths and doses interact with biological systems.
Results depend on the device, wavelength, irradiance, exposure time,
treatment area, and study population. Research on one device or protocol
should not be assumed to apply to every consumer or wellness panel.

Follow manufacturer instructions and discuss personal medical
questions, photosensitivity, medications, eye protection, and treatment
expectations with a qualified professional.

Questions to ask before
moving forward

1. What is the exact product, drug, device, or procedure name?
2. Who manufactured or processed it?
3. What is its intended use and current regulatory status?
4. Is this use FDA-approved, FDA-cleared, part of a clinical trial,
   compounded for an identified patient need, or otherwise
   investigational?
5. What human evidence supports this exact product and proposed
   use?
6. What are the known and uncertain risks?
7. What alternatives are available?
8. Who will perform the procedure or supervise treatment?
9. What follow-up and adverse-event plan is in place?
10. What costs are included, and what happens if additional care is
    needed?

Warning signs

• A product is promoted as a cure for many unrelated conditions.
• Results are described as guaranteed or risk-free.
• The product name, manufacturer, labeling, or regulatory status is
  withheld.
• Research on a broad mechanism is presented as proof of a specific
  product outcome.
• There is no meaningful discussion of risks, alternatives,
  uncertainty, or follow-up.
• You are pressured to pay before receiving clear information or
  informed-consent materials.

Trusted starting points

• NIH Stem
  Cell Basics
• FDA
  information about regenerative medicine products
• ISSCR
  Patient Guide to Stem Cell Treatments
• ClinicalTrials.gov
• FDA
  consumer and healthcare-professional compounding information
• BioCellara research
  library

Disclaimer: This page is general education, not medical advice. A
licensed healthcare professional who knows the patient’s history must
evaluate risks, benefits, alternatives, and eligibility.